期刊
CLINICAL INFECTIOUS DISEASES
卷 55, 期 -, 页码 S88-S92出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cis335
关键词
-
资金
- Optimer Pharmaceuticals, Inc.
- Merck
- Viropharma
- Optimer
There are few high-quality studies of the costs of Clostridium difficile infection (CDI), and the majority of studies focus on the costs of CDI in acute-care facilities. Analysis of the best available data, from 2008, indicates that CDI may have resulted in $4.8 billion in excess costs in US acute-care facilities. Other areas of CDI-attributable excess costs that need to be investigated are costs of increased discharges to long-term care facilities, of CDI with onset in long-term care facilities, of recurrent CDI, and of additional adverse events caused by CDI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据